ANIX: Anixa Bio Company Value to Net Income

Anixa Biosciences - graphic logo of issuer ANIX

Anixa Biosciences, Inc. (ANIX) focuses on developing advanced methods for tumor prevention and detection by advancing CAR-T systems and vaccination. Current research expenditures are weighing on profits, keeping profitability at a stable level. Project success depends on patents and trial data, while the PE ratio stands at -8.70. The price action displayed on GURU.Markets allows for a real-time assessment of this biopharmaceutical asset's market value.

Price to Earnings Ratio: Anixa Biosciences Inc (ANIX) for 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Anixa Biosciences (ANIX)

Comprehensive company analysis:Anixa ANIX
Signature product of Anixa

Anixa Biosciences, Inc. (ANIX) holds an exceptional status in oncology due to the trust of the Cleveland Clinic. This indicator measures the return on investment by comparing market capitalization with net profit to assess business value. By analyzing the company's earnings multiple, an investor determines the extent of the premium paid for the asset's future cash flows. The high authority of the brand's developments justifies the fundamental stability of the share price even at premium multiples.